伊诺维奥制药 INO 深 沪
已收盘 11-14 16:00:00 美东时间
2.05
+0.100
+5.13%
华盛通- 最 高2.10
- 今 开1.98
- 成交量 148.76万股
- 最 低 1.95
- 昨 收 1.95
- 总市值 1.09亿
- 52周最高 4.61
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.30
- 委 比 40.31%
- 总股本 5314.27万
- 历史最高 405.48
- 量 比 0.89
- 振 幅 7.69%
- 历史最低 1.30
- 每 手 1
- 风险率 0.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Raises Price Target to $6
Piper Sandler analyst Edward Tenthoff reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and raises the price target from $5 to $6.
今天 00:06
Inovio Pharmaceuticals drops 6%, proposes equity offering
Inovio Pharmaceuticals (INO) proposed an underwritten public offering of its common stock, with all shares in the offering to be sold by the company itself. The underwriters have a 30-day option to pu...
11-11 14:33
Inovio outlines mid-2026 launch for INO-3107 as BLA submission progresses
Earnings Call Insights: Inovio Pharmaceuticals (INO) Q3 2025 Management View CEO Jacqueline Shea highlighted, “we have achieved our primary objective for this year, which is completing the rolling sub...
11-11 08:32
INOVIO Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed
NOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
11-11 07:14
Inovio Pharmaceuticals Q3 EPS $(0.87) Misses $(0.42) Estimate
Inovio Pharmaceuticals (NASDAQ:INO) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.42) by 105.67 percent. This is a 2.25 percent increase over losses of $(0.89) per
11-11 05:03
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors
Nurix Therapeutics announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, with over two decades of leadership in drug development and commercialization, previously served as Chief Development Officer and Chief Oncology Officer of Pfizer Oncology. His expertise will strengthen Nurix’s efforts in advancing its lead asset, bexobrutideg, for chronic lymphocytic leukemia and exploring protein degradation in autoimmune ...
11-10 12:00
Inovio Pharmaceuticals Q3 2025 Earnings Preview
Inovio Pharmaceuticals (INO) is scheduled to announce Q3 earnings results on Monday, November 10th, after market close. The consensus EPS Estimate is -$0.48 (+46.1% Y/Y)Over the last 2 years, INO has ...
11-10 06:35
Earnings week ahead: DIS, CSCO, OXY, PLUG, B, AMAT, JD, BYND, PSKY, and more
Earnings in the upcoming week will spotlight a diverse lineup across media, technology, energy, aerospace, and consumer sectors. The Walt Disney Company (DIS) and Paramount Skydance (PSKY) will be in ...
11-09 21:16
Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine
Publication includes complete data for all participants (n=39) up to week 72, further demonstrating durable and tolerable expression of DMAbs Effective target binding and confirmed functiona...
10-21 20:05
